Navigation Links
National award honors CHOP scientist for career work in gene therapy for hemophilia
Date:12/13/2013

Katherine A. High, M.D., of The Children's Hospital of Philadelphia (CHOP) was honored for her trailblazing scientific and clinical research in the bleeding disorder hemophilia when she received the 2013 E. Donnall Thomas Prize from the American Society of Hematology (ASH) at its annual meeting on Dec. 9 in New Orleans.

Named for the late Nobel Prize laureate E. Donnall Thomas, the award recognizes pioneering research achievements in hematology that have helped move the field forward. An internationally recognized expert in the molecular basis of hemophilia, Dr. High has developed novel approaches to correcting hemophilia with gene therapy in studies over the past two decades. Her studies continue today in a current NIH-funded clinical trial for hemophilia.

The Prize recipient customarily delivers the E. Donnall Thomas Lecture to the ASH conference audience. Dr. High's lecture, "Sailing to Ithaca: Gene Therapy's Odyssey from Investigational Agent to Therapeutic Product," described the successes and obstacles of the evolving science and practice of gene therapy as it pursues the goal of offering long-lasting treatments of previously incurable diseases.

In presenting the E. Donnall Thomas Prize, ASH president Janis L. Abkowitz, M.D., said, "Dr. High is unquestionably a leader in gene therapy and has made remarkable, groundbreaking contributions to the field, demonstrating creativity, determination, and the ability to overcome numerous obstacles. Through her countless discoveries, Dr. High has transformed the notion of utilizing genetically engineered mechanisms for treatment of incurable inherited disorders from a distant vision to reality."

Dr. High is the founder and director of the Center for Cellular and Molecular Therapeutics at The Children's Hospital of Philadelphia. She also is a Howard Hughes Medical Institute Investigator, the William H. Bennett Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania, and an attending physician at CHOP. A former president of the American Society of Gene and Cell Therapy, she also is an elected member of both the Institute of Medicine and the American Academy of Arts and Sciences. She is a scientific co-founder and advisor to Spark Therapeutics, a fully integrated gene therapy company launched in October 2013 with a capital investment from CHOP.


'/>"/>

Contact: John Ascenzi
ascenzi@email.chop.edu
267-426-6055
Children's Hospital of Philadelphia
Source:Eurekalert  

Related biology news :

1. Researchers named to National Academy of Inventors
2. Kurt H. Becker Named a Fellow of the National Academy of Inventors
3. University of Tennessee vice chancellor named National Academy of Inventors Fellow
4. First International Bioenergy Conference brings together world-leading experts
5. International gene therapy trial for bubble boy disease shows promising early results
6. OU professor receives national fellowship to complete biography on Ancel Keys and the American diet
7. 20th International AIDS Conference (AIDS 2014) plenary speakers announced
8. National survey finds frog abnormalities are rare
9. China National Genebank initiates collaboration to sequence transcriptomes of 1,000 fish species
10. Women & Infants earns $3 million grant from National Institutes of Health
11. Antibiotic resistance is a international issue that better education can address
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
National award honors CHOP scientist for career work in gene therapy for hemophilia
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
(Date:3/23/2017)... DUBLIN , Mar. 23, 2017 Research ... Anti-Theft System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 8.8% over the next ... This industry report analyzes the market estimates and forecasts for all ...
(Date:3/20/2017)... 2017 At this year,s CeBIT Chancellor Dr. ... DERMALOG. The Chancellor came to the DERMALOG stand together with the Japanese ... CeBIT partner country. At the largest German biometrics company the two government ... and iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
Breaking Biology News(10 mins):
(Date:4/25/2017)... Linda, Ca (PRWEB) , ... April 25, 2017 , ... ... webinar in the series will explore the laboratory testing for DIC in order to ... serious hypercoagulable disorder which can occur in hospitalized patients resulting in a high degree ...
(Date:4/25/2017)... , April 25, 2017 ... ("EpiVax") has licensed its novel immune-modulating technology to an ... disease and allergy. Tregitopes, pronounced T·rej·itopes, ... human immunoglobulin by EpiVax CEO Annie De ... to intravenous immunoglobulin G, an autoimmune disease therapy, ...
(Date:4/25/2017)... ... April 25, 2017 , ... Leaders of Quorum ... will be featured in multiple sessions at this week’s Association of Clinical Research ... to best practices in clinical research. , "We are excited to present subject matter ...
(Date:4/21/2017)... ... 2017 , ... The 2017 Colorado Manufacturing Awards celebrates Innovation ... and well as the first-year award for 2017 Manufacturing Women of the Year. ... by CompanyWeek and Manufacturers Edge, among other sponsors. , The Colorado Manufacturing ...
Breaking Biology Technology: